Human induced pluripotent stem cells (iPSCs) represent a unique opportunity for regenerative medicine because they offer the prospect of generating unlimited quantities of cells for autologous transplantation, with potential application in treatments for a broad range of disorders 1-4 . However, the use of human iPSCs in the context of genetically inherited human disease will require the correction of disease-causing mutations in a manner that is fully compatible with clinical applications 3,5 . The methods currently available, such as homologous recombination, lack the necessary efficiency and also leave residual sequences in the targeted genome 6 . Therefore, the development of new approaches to edit the mammalian genome is a prerequisite to delivering the clinical promise of human iPSCs. Here we show that a combination of zinc finger nucleases (ZFNs) 7 and piggyBac 8,9 technology in human iPSCs can achieve biallelic correction of a point mutation (Glu342Lys) in the a 1 -antitrypsin (A1AT, also known as SERPINA1) gene that is responsible for a 1 -antitrypsin deficiency. Genetic correction of human iPSCs restored the structure and function of A1AT in subsequently derived liver cells in vitro and in vivo. This approach is significantly more efficient than any other gene-targeting technology that is currently available and crucially prevents contamination of the host genome with residual non-human sequences. Our results provide the first proof of principle, to our knowledge, for the potential of combining human iPSCs with genetic correction to generate clinically relevant cells for autologous cell-based therapies.
Human induced pluripotent stem cells (iPSCs) represent a unique opportunity for regenerative medicine because they offer the prospect of generating unlimited quantities of cells for autologous transplantation, with potential application in treatments for a broad range of disorders [1] [2] [3] [4] . However, the use of human iPSCs in the context of genetically inherited human disease will require the correction of disease-causing mutations in a manner that is fully compatible with clinical applications 3, 5 . The methods currently available, such as homologous recombination, lack the necessary efficiency and also leave residual sequences in the targeted genome 6 . Therefore, the development of new approaches to edit the mammalian genome is a prerequisite to delivering the clinical promise of human iPSCs. Here we show that a combination of zinc finger nucleases (ZFNs) 7 and piggyBac 8, 9 technology in human iPSCs can achieve biallelic correction of a point mutation (Glu342Lys) in the a 1 -antitrypsin (A1AT, also known as SERPINA1) gene that is responsible for a 1 -antitrypsin deficiency. Genetic correction of human iPSCs restored the structure and function of A1AT in subsequently derived liver cells in vitro and in vivo. This approach is significantly more efficient than any other gene-targeting technology that is currently available and crucially prevents contamination of the host genome with residual non-human sequences. Our results provide the first proof of principle, to our knowledge, for the potential of combining human iPSCs with genetic correction to generate clinically relevant cells for autologous cell-based therapies.
At present, available methods for gene targeting rely on positive selection to isolate rare clones that have undergone homologous recombination. To remove the unwanted selection cassettes, Cre/ loxP or Flp/FRT recombination systems are used, which leave behind single loxP or FRT sites 10, 11 . These small ectopic sequences have the potential to interfere with transcriptional regulatory elements of surrounding genes 12 , most of which are not fully characterized in the human genome. An alternative method to remove selection cassettes is to convert them into transposons. The most suitable transposon for this purpose is piggyBac, a moth-derived DNA transposon, which can transpose efficiently in mammalian cells including human embryonic stem (ES) cells 9, 13 . A remarkable feature of this mobile element is seamless excision, which enables the removal of transgenes flanked by piggyBac inverted repeats without leaving any residual sequences 9, 14 .
To explore the use of piggyBac for the correction of point mutations, we designed a vector to correct an albino mutation (G290T substitution in the Tyr gene) in mouse iPSCs isolated from fibroblasts of the C57Bl6-Tyr c-Brd strain 15 . The targeting vector was constructed, carrying a wild-type 290G sequence and a PGK-puroDtk cassette flanked by piggyBac repeats into the TTAA site ( Fig. 1a ). After isolation of targeted clones, the selection cassette was excised from the mouse iPSC genome by transient expression of the piggyBac transposase and subsequent 1- (FIAU) selection. Genomic modification was verified by Southern blot and polymerase chain reaction (PCR) analyses ( Fig. 1b, c) . The correction of the G290T mutation and seamless piggyBac excision were confirmed by sequence analyses (Fig. 1d, e ). Two introduced silent mutations were observed, confirming that the T290G substitution was mediated by gene correction, not by spontaneous reversion (Fig. 1e ). The function of the reverted allele was tested by injecting the corrected mouse iPSCs into albino mouse blastocysts. The resulting chimaeric mice had a black coat colour, indicating phenotypic correction of the albino mutation ( Fig. 1f) . These results collectively demonstrate that the piggyBac transposon can be used as a versatile tool for highly precise modification (for example, correction or mutation) of the mammalian genome at a single base-pair level. We next explored whether this approach could be used to correct a mutation in human iPSCs derived from individuals with a 1 -antitrypsin deficiency (A1ATD) 16 . A1ATD is an autosomal recessive disorder found in 1 out of 2,000 individuals of North European descent and represents the most common inherited metabolic disease of the liver 17, 18 . It results from a single point mutation in the A1AT gene (the Z allele; Glu342Lys) that causes the protein to form ordered polymers within the endoplasmic reticulum of hepatocytes 17, 18 . The resulting inclusions cause cirrhosis for which the only current therapy is liver transplantation. The increasing shortage of donors and harmful effects of immunosuppressive treatments impose major limitations on organ transplantation, making the potential of human iPSC-based therapy highly attractive. Because homologous recombination is relatively inefficient in human ES cells 6 we used ZFN technology, which stimulates gene targeting in human ES cells as well as human iPSCs 7, 10, 19 . ZFN pairs were designed to specifically cleave the site of the Z mutation ( Fig. 2a -c, Supplementary Table 1 and Supplementary Note). A targeting vector was constructed from isogenic DNA with piggyBac repeats flanking the PGK-puroDtk cassette ( Fig. 2a ). To minimize the distance between the mutation and the piggyBac transposon, a CTG leucine codon, 10-bp upstream of the mutation, was altered to a TTA leucine codon, generating the TTAA sequence, which would be left in the genome following piggyBac excision ( Fig. 2b) .
Puromycin-resistant human iPSC colonies obtained after coelectroporation of ZFN expression vectors and the targeting vector were screened for targeted clones by PCR. A1ATD-iPSC lines derived from three different patients yielded targeted clones (Table 1) . Remarkably, 54% of the puromycin-resistant colonies were targeted on one allele, whereas 4% were the result of simultaneous targeting of both alleles ( Supplementary Fig. 1 ).
To remove the piggyBac-flanked selection cassette from these modified clones, we transiently transfected two homozygously targeted clones (B-16 and C-G4) with a hyperactive form of the piggyBac transposase 8 and subjected them to FIAU selection. The genotype of the resulting FIAU-resistant colonies was analysed by PCR and confirmed by Southern blot ( Fig. 2d and Supplementary Fig. 2a ). Biallelic excision was observed in 11% of FIAU-resistant colonies ( Table 2 ). Sequence analyses demonstrated that the Z mutation was corrected on both alleles and that transposon excision yielded a TTAA sequence as initially planned (Fig. 2b, e and Supplementary Fig. 2b ). The resulting corrected iPSC lines maintained the expression of pluripotency markers for more than 20 passages and their abilities to differentiate into cells expressing markers of the three germ layers ( Supplementary Fig. 3 ), indicating that genome modification did not alter the pluripotency of corrected human iPSCs.
Genomic instability is known to be associated with prolonged culture of human ES cells 20, 21 and mutations arising during genome modification would be another concern for clinical application of human iPSCs. Therefore, we analysed the genomic integrity of the human iPSC lines using comparative genomic hybridization (CGH) ( Supplementary  Table 2a -c). Two out of three A1ATD-iPSC primary lines differed from their parental fibroblasts, showing amplifications or deletions ranging from 20 kb to 1.3 Mb, including a gain of 20q11.21, a frequently amplified region in human ES cells 22, 23 (see Supplementary Analysis and Supplementary Fig. 4 ). Line A retained a normal genome content compared to its parental fibroblast. Reassuringly, we found that after ZFN-stimulated targeting, four out of six homozygous clones had unaltered genomes compared to their parental iPSC lines. Sixteen cell 
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lines with biallelic piggyBac excision were compared with their corresponding primary iPSCs and 12 had unaltered genomes. We also analysed the iPSC lines by SNP arrays to check for loss of heterozygosity and found that all lines analysed retained heterozygosity throughout their genome ( Supplementary Fig. 5 ). This observation demonstrates that biallelic gene correction was the result of simultaneous homologous recombination followed by simultaneous excision at both alleles and that mitotic recombination was not involved in this process. ZFN off-target cleavage and imprecise excision after multiple piggyBac transposition might introduce mutations into the genome. To investigate these possibilities at a single base-pair resolution, we sequenced exomes of the corrected B-16-C2 line and its parental fibroblast. Comparison of these exomes identified 29 mutations (Supplementary Table 3 ). The genesis of these mutations was determined by analysis of the primary iPSC line and the homozygously targeted intermediate. Twenty-four point mutations and one 1-bp deletion were detected in the primary iPSC line and four mutations arose during genetic correction: one during targeting and three during piggyBac excision. These mutations seemed to arise during culture as their genomic signatures were inconsistent with ZFN off-target sites or piggyBac integration sites (Supplementary Analysis). Taken together, we conclude that the combination of ZFNs with piggyBac provides a new method for rapid and clean correction of a point mutation in human iPSCs without affecting their basic characteristics.
To confirm that the genetic correction of A1ATD-iPSCs resulted in the expected phenotypic correction, iPSCs were differentiated in vitro into hepatocyte-like cells, the main cell type affected by the disease A1ATD. Differentiation of the corrected lines occurred as expected, resulting in a near homogenous population of hepatocyte-like cells ( Supplementary Fig. 6a-c) . Remarkably, CGH analysis of differentiated cells showed that hepatic differentiation neither increases the number of genetic abnormalities nor selects for cells with abnormal karyotype ( Supplementary Table 2d ). The resulting cells shared key functional attributes of their in vivo counterparts including glycogen storage, low density lipoprotein (LDL)-cholesterol uptake, albumin secretion and cytochrome P450 activity ( Supplementary Fig. 6d-g) . Importantly, immunofluorescence and enzyme-linked immunosorbent assay (ELISA) both confirmed the absence of mutant polymeric A1AT in corrected iPSC-derived hepatocyte-like cells that instead efficiently secreted normal endoglycosidase-H-insensitive monomeric A1AT ( Fig. 3a-d ). In addition, secreted A1AT showed an enzymatic inhibitory activity that was comparable to that obtained from normal adult hepatocytes (Fig. 3e) , thereby suggesting that physiological restoration of enzyme inhibitory activity could be achieved.
Lastly, the in vivo function of corrected iPSC-derived hepatocytelike cells (B-C16-2 line) was assessed following transplantation into the liver of Alb-uPA 1/1 ;Rag2 2/2 ;Il2rg 2/2 mice via intrasplenic injection. Livers harvested 14 days after injection were colonized by human cells identified using antibodies specific to human albumin and A1AT (Fig. 3f, g) . These human hepatocyte-like cells were distributed throughout the liver lobes and were seen to be integrated into the existing mouse parenchyma (Fig. 3f, g) . In addition, human albumin was detected in the serum of transplanted animals for at least 5 weeks (Fig. 3h ), whereas no tumour formation was detected in any mice. Therefore, corrected iPSC-derived hepatocyte-like cells were able to colonize the liver in vivo and show functional activities characteristic of their human ES-cell-derived counterparts 24 . Collectively these analyses demonstrate that genetic correction of the Z mutation resulted in functional restoration of A1AT in patient-derived cells.
All the experimental evidence described earlier strongly supports the applicability of genetic correction in patient-specific iPSCs for cellbased therapy of A1ATD. We therefore repeated the genetic correction in more clinically relevant cells using patient-specific iPSCs reprogrammed from fibroblasts with Sendai virus vectors, an integrationfree method 25 ( Supplementary Fig. 7a-f ). One primary human iPSC line with an intact genome by CGH analysis ( Supplementary Fig. 7e and Supplementary Table 4 ) was corrected by the method described earlier. The final product, iPSC-3-G5-A7, had the corrected A1AT, an intact genome compared to the parental fibroblast and expressed normal A1AT protein when differentiated to hepatocyte-like cells ( Supplementary Fig. 8 and Supplementary Table 4 ). This is the first demonstration, to our knowledge, of the generation of mutationcorrected patient-specific iPSCs, which could realize the therapeutic promise of human iPSCs. B-16  88  15  17  33  38  C-G4  94  5  5  19 20 Mean frequency (%) 11 29 All 
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Here we demonstrate that ZFNs and piggyBac transposons enable simultaneous biallelic correction of diseased human iPSCs. No residual ectopic sequences remain at the site of correction and the genome seems to be undisturbed elsewhere. Although we could readily obtain cell lines without large genomic alterations during genetic modification, the resulting corrected human iPSCs carry 29 mutations in protein-coding exons, of which 22 were non-synonymous or splice site mutations. The probable impact of this mutation load needs to be considered in the context of the likely functional impact of the mutations, taking into account the normal germline load, accumulated somatic variation, the presence of compensating normal gene copies and the requirement for the gene product in the derived differentiated cells. From this point of view, only eight mutations might affect gene functions in hepatocytelike cells ( Supplementary Table 3 ). Nevertheless, the corrected iPSCs could efficiently differentiate to hepatocyte-like cells and engraft into the animal model for liver injury without tumour formation. Therefore, limited genomic abnormalities might have restricted biological consequences. Careful screening of primary and corrected human iPSCs using deep sequencing analyses would contribute to the safe use of human iPSCs in clinical applications.
iPSCs derived from different patients were effectively corrected, demonstrating that this method could be applied to a large number of A1ATD-iPSC lines. Because the biallelic correction could be carried out in less than 4 months, our approach may be compatible with largescale production of corrected patient-specific iPSCs not only for A1ATD but also for other monogenic disorders.
METHODS SUMMARY
A1ATD-iPSCs were described previously 16 . 23 10 6 human iPSCs were cotransfected with ZFN expression vectors and the donor template, and subjected to puromycin selection (1 mg ml 21 ) initiated 4 days after transfection. For transposon excision, targeted cells were transfected with pCMV-hyPBase 8 , cultured for 4 days, re-plated and selected in 250 nM FIAU. To increase clonogenicity, cells were treated with ROCK inhibitor 26 , Y-27632 (10 mM) 4 h before dissociation and 24 h after plating. Resulting colonies were picked 2 weeks later, analysed by PCR and further verified by Southern blot analysis. Primer sequences are listed in Supplementary Table 5 .
METHODS
Plasmid construction. Gateway-adapted piggyBac transposon vectors: a destination vector pPB-R1R2-NP was constructed as follows. The attR1 and attR2 sites were PCR-generated and digested by NheI/HindIII and XhoI/SpeI, respectively. EM7-neo was PCR-generated and digested by HindIII/XhoI. These three fragments were then cloned into the NheI-SpeI site of pPB-LR5 (ref. 27) , resulting in pPB-R1R2-Neo. An EcoRI-XbaI fragment containing PheS was excised from pR6K-R1R2-ZP 28 , blunt-ended and cloned into the blunted XhoI site of pPB-R1R2-Neo, resulting in pPB-R1R2-NP. An entry vector pENTR-PGKpuroDtk was constructed by cloning a KpnI-NotI PGK-puroDtk fragment into the KpnI-NotI site of pENTR-2B.
A targeting vector for Tyr: the targeting vector was constructed using BAC recombineering. A bacterial artificial chromosome (BAC) clone RP24-221M7 was introduced into Escherichia coli strain EL350 (ref. 29) . A mini targeting vector was first constructed to modify the Tyr gene on the BAC. Left and right homology arms were PCR-generated and digested by AscI/BsiWI and NsiI/PacI, respectively. The transposon fragment was excised from pPB-R1R2-NP by NsiI/BsiWI digestion. These three fragments were then cloned into the AscI/PacI site of pMCS, resulting in pMCS-Tyr-NP. An AscI-PacI fragment was excised from pMSC-Tyr-NP and used for BAC targeting. A retrieving vector was constructed by cloning PCR-generated left and right homology arms into the XhoI/AscI site of pMSC-DTA, following AscI/HindIII and XhoI/HindIII digestion of the left and right arm, respectively. The retrieving vector was linearized by HindIII digestion and used to retrieve the 3.0-kb 59 arm, the transposon and the 6.5-kb 39 arm. Lastly, the Neo-PheS cassette was replaced with the PGK-puroDtk cassette by Gateway cloning, resulting in pDTA-Tyr PB . The targeting vector was linearized by AscI before electroporation into the albino miPSCs.
A donor template vector for A1AT: a 2-kb fragment, which contained 1 kb on both sides of the Z mutation, was first PCR-amplified using genomic DNA from A1ATD-iPSC line B as a template and cloned into pCR4-blunt-TOPO (Invitrogen), resulting in pCR4-AAT_Z. To construct a donor template with corrected sequence and a piggyBac transposon, the 59 arm and 39 arm were PCR-amplified and digested with AscI/NsiI and BsiWI/PacI, respectively. The NsiI-BsiWI fragment containing a piggyBac transposon with the Neo-PheS cassette was excised from pPB-R1R2-NP. The digested fragments were cloned into the AscI-PacI site of pMCS, resulting in pMCS-AAT-PB:NP. The Neo-PheS cassette was subsequently replaced with a PGK-puroDtk cassette by Gateway cloning, resulting in the final donor vector, pMCS-AAT-PB:PGKpuroDtk.
The plasmids (pPB-R1R2-NP, pENTR-PGKpuroDtk, pMCS-AAT-PB:PGKpuroDtk) have been deposited in the Wellcome Trust Sanger Institute Archives and are available upon request (http://www.sanger.ac.uk/technology/ clonerequests/). Cell culture. Appropriate ethical approval and patient consent were obtained (Ethics reference no. 08/H0311/201; R&D no. A091485). A1ATD-iPSCs (ref. 16 ; A, patient 2 line 1; B, patient 1 line1; C, patient 3 line 1) were cultured on mouse embryonic fibroblast (MEF)-feeder layers in human ES cell medium: DMEM/F12 supplemented with 20% knockout serum replacement, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 13 non-essential amino acids and 4 ng ml 21 FGF2 (Invitrogen). Subculture was performed every 5-7 days by detaching human iPSCs by incubation in 0.5 mg ml 21 dispase and 0.5 mg ml 21 collagenase type IV for 1 h at 37 uC, collecting detached human iPSC colonies, breaking down into small clamps and plating them onto new feeder plates. MEFs (CF1 or B6129F1) were cultured in DMEM containing 10% FCS, 2 mM glutamine, 0.1 mM 2-melcaptoethanol and 13 nonessential amino acids. Mouse iPSCs (iPS25D1; ref. 15 ) were cultured on MEF-feeder layers in mouse ES cell medium: KO-DMEM supplemented with 15% FBS, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 13 non-essential amino acids and 1,000 unit ml 21 LIF (Millipore). Gene targeting and transposon excision in mouse iPSCs. 1 3 10 7 cells were electroporated with 25 mg of a linearized targeting vector in 800 ml of HEPESbuffered saline using a Gene Pulser II electroporator (230 V, 500 mF) and plated onto three 10-cm dishes. The next day, puromycin selection (1 mg ml 21 ) was initiated. Resulting colonies were picked and screened by PCR. Targeted clones were expanded and further verified by Southern blot analysis. Correctly targeted clones were then subjected to transposon excision. 2 3 10 6 cells were electroporated with 40 mg of pCMV-hyPBase in 800 ml of HEPES-buffered saline using a Gene Pulser II electroporator (230 V, 500 mF) and plated onto one well of a 6-well plate. After passage once, cells were replated on day 4 at 5 3 10 5 cells per 10-cm dish. On the following day, FIAU (0.2 mM) selection was initiated. On day 5 of selection, FIAU was withdrawn. Resulting colonies were picked at day 7 and screened by PCR. Primer sequences to detect homologous recombination are shown in Supplementary Table 5 . ZFN-mediated gene targeting in A1ATD-iPSCs. On the day of electropolation (day 0), near-confluent cells were pre-treated with a ROCK inhibitor 26 (Y-27632, Sigma) at 10 mM for 3-4 h before electroporation. Cells were then washed with PBS once, detached by Accutase (Millipore; 10 min at 37 uC) and mixed with DMEM/ F12 containing 10% FCS. Cells were dissociated into single-cell suspension by vigorous pipetting and counted. 2 3 10 6 cells were pelleted and mixed with 5 mg of a 59-ZFN expression vector, 5 mg of a 39-ZFN expression vector and 2 mg of the donor template in 100 ml of human ES cell solution 1 (Lonza). The cell suspension was transferred to a cuvette and electroporated using the Amaxa Nucleofector device (Lonza) with program A23. The electroporated cells were plated onto one or two 10-cm feeder dishes in MEF-conditioned human ES cell medium containing 10 mM Y-27632. Human ES cell medium without any drug was used for daily medium change between days 1-3. On day 4, puromycin selection (1 mg ml 21 ) was started. On day 6, medium was changed to MEF-conditioned human ES cell medium containing 0.5 mg ml 21 puromycin, which was used for medium change at every other day until picking colonies. Resulting colonies were picked on day 13-17. Colonies were cut into two pieces. One half was transferred onto one well of a 24-well feeder plate and the other half was lysed and used for PCR genotyping. PCR-positive clones were further expanded and homologous recombination was verified by Southern blot analysis. Transposon excision in homozygously targeted human iPSCs. Homozygously targeted clones (B-16, C-G4, SeV-1-C3 and SeV-3-G5) were used for transposon removal. Line-A-derived clones were omitted because this line showed a lower capability of differentiating into endodermal lineages. Cells were prepared as described earlier. 2 3 10 6 cells were mixed with 10 mg of the hyperactive piggyBac transposase expression vector (pCMV-hyPBase 8 ) in 100 ml of human ES cell solution 1 and electroporated using the Nucleofector device with the program A23. Electroporated cells were plated onto a 6-well plate in 1:2, 1:3 and 1:6 dilutions in MEF-conditioned human ES cell medium containing 10 mM Y-27632. Note that ROCK inhibitor was added to the culture medium until day 6 in this experiment. On day 2, cells with ,80% confluency were passaged using Accutase at a split ratio of 1:2, 1:3 and 1:6 into 6-well plates. On day 4, cells with ,80% confluency were washed with PBS, detached with Accutase, suspended in human ES cell medium and pelleted. Cells were resuspended in human ES cell medium into single-cell level and counted. 1 3 10 4 cells were then plated onto one 10-cm dish in human ES cell medium containing 10 mM Y-27632. 16-18 h after plating (day 5), medium was changed to human ES cell medium containing 0.25 mM FIAU and 10 mM Y-27632. On day 6, medium was changed to human ES cell medium containing 0.25 mM FIAU and then medium was changed every other day. Genotype and deletion of the piggyBac transposon were analysed by PCR and further verified by Southern blot analysis. CGH analysis. Genomic DNA was extracted using a DNeasy kit (Qiagen). Agilent 244K human genome arrays were used following the manufacturer's protocol. The arrays were scanned with an Agilent microarray scanner and data were generated by Agilent Feature Extraction software. CGH calls were made with Agilent's DNA analytics software using the ADM2 algorithm (6.0 threshold) with a minimum of 5 probes in the region as a filter. SNP analysis. An Illumina HumanCytoSNP-12 SNP array was used following the manufacturer'sprotocol.GenotypecallswereperformedbyIllumina'sGenomeStudio. B allele frequency and log R ratio were analysed by KaryoStudio. CNVpatition v2.4.4 bundled in KaryoStudio was used for copy number analysis. ZFN design. ZFNs were designed against a region containing the Z mutation in the A1AT gene (see Fig. 2a , b) and assembled as previously described 30 . The amino acid residues at positions '21' to '16' of the recognition a-helix 31,32 of each of the zinc finger DNA-binding domains for each DNA triplet target are shown in Supplementary Table 2 . The ZFNs were linked to the wild-type FokI catalytic domain. The activity of the ZFN at the endogenous target site was determined using the Surveyor Nuclease assay as previously described 33 . Human iPSC-derived hepatocyte-like cell transplantation. All mice were housed in pathogen-free conditions and animal studies were approved by the committee on animal experimentation of the Institut Pasteur and by the French Ministry of Agriculture. Differentiated cells (5 3 10 5 cells per animal in 50 ml DMEM) were injected into the spleens of 3-to 4-week-old Alb-uPA 1/1 ;Rag2 2/2 ;Il2rg 2/2 mice (n 5 7). The recipient mouse was killed 2 weeks after transplantation for histological analysis. Blood samples were collected and human albumin in plasma was quantified by ELISA (Bethy Laboratories). Frozen liver sections were analysed by immunofluorecence with human albumin (Dako) or human A1AT (Dako) specific antibodies. Non-transplanted mice were used as controls. Exome sequencing. The corrected iPSC line, B-16-C2, and its parental fibroblasts were analysed. Exome sequencing and analysis were performed as described previously 34 with minor modifications. Exome pull-down was performed using an Agilent SureSelect Human All Exon 50Mb Kit according to the manufacturer's instructions. Enriched DNA was sequenced on an Illumina HiSeq 2000 (75-bp paired-end sequencing). 90.32% (Fibroblast-B) and 90.72% (B-16-C2) of total targeted regions were covered with more than 103 sequencing depth, LETTER RESEARCH
